A prospective study of serum folate levels in patients with solid tumors treated with olaparib
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf321 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2025. Verfasst von Jamile Shammo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, 60611, United S…. Hauptthemen laut MEDLINE: Folic Acid, Folic Acid Deficiency, Neoplasms, Phthalazines. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Background
Olaparib is a polyadenosine 5’-disphosphoribose polymerase inhibitor approved to treat advanced ovarian cancers with germline mutations. The link between olaparib-induced anemia and folate deficiency was described in a retrospective case series in which 87.5% of patients developed concomitant folate deficiency and anemia. We sought to prospectively evaluate this association. Patients and Methods This is an open-label prospective trial of patients with solid tumors treated with olaparib to determine the frequency and timing of folate deficiency anemia. Patients who developed grade 1 anemia (Hgb < 12.0 g/dL) concomitantly with folate deficiency (serum folate < 7.0 ng/mL) were randomized to receive placebo or folic acid. Secondary endpoints included the impact of folic acid supplementation on serum folate and hemoglobin, transfusion needs, and need for olaparib treatment interruption, dose reduction, or drug discontinuation.
Results
Nine subjects were enrolled, with ovarian or breast cancer. Two patients were randomized to forgo folate supplementation, two were randomized to receive folate, and the rest were not randomized per protocol. Three withdrew due to disease progression. All patients demonstrated decreased folate levels after initiation of olaparib, eight occurring within 3 months. Seven patients developed a concomitant grade 1 anemia. Folate deficiency did not correlate with clinically significant anemia.
Conclusions
This trial demonstrated folate deficiency in nearly all patients starting olaparib within weeks but, deficiencies did not result in a clinically significant anemia. Folate levels normalized with supplementation and improved with olaparib discontinuation. This data warrant checking serum folate in patients receiving olaparib who develop anemia and replacing folate if deficiency is found.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, 60611, United States.
- Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, 60612, United States.
- Division of Hematology, Oncology, and Stem Cell Transplant, Department of Medicine, Rush University Medical Center, Chicago, Illinois, 60612, United States.
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Rush University Medical Center, Chicago, Illinois, 60612, United States.
ORCID-Profile: Laura Owczarzak, Ruta Rao
Förderung
- AstraZeneca
Zitieren
APA
Shammo, J., Owczarzak, L., Yun, N. K., Winkelman, L., Basu, S., Rao, R., Ahmed, A., Dewdney, S., Cobleigh, M., & Usha, L. (2025). A prospective study of serum folate levels in patients with solid tumors treated with olaparib. The Oncologist. https://doi.org/10.1093/oncolo/oyaf321
Vancouver
Shammo J, Owczarzak L, Yun NK, Winkelman L, Basu S, Rao R, et al. A prospective study of serum folate levels in patients with solid tumors treated with olaparib. The Oncologist. 2025. doi:10.1093/oncolo/oyaf321
BibTeX
@article{Shammo2025,
author = {Shammo, Jamile and Owczarzak, Laura and Yun, Nicole K and Winkelman, Lois and Basu, Sanjib and Rao, Ruta and Ahmed, Amina and Dewdney, Summer and Cobleigh, Melody and Usha, Lydia},
title = {A prospective study of serum folate levels in patients with solid tumors treated with olaparib},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf321}
}
EUVIMED